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Introduction
Mevalonate kinase deficiency (MKD) has a wide spec-
trum and severity of clinical manifestation. Patients with
mutations in MVK gene leading to complete lack of the
enzyme, suffer from the most severe form of disease,
also known as mevalonic acydosis, whereas defects with
preserved, but insufficient enzyme activity present with
autoinflammatory syndrome , also known as hiperIgD
syndrome (HIDS). Both diagnosis and treatment of
MKD is a great challenge for clinicians. Hematopoietic
stem cell transplantation (HSCT) is the only available
therapy that allows delivery to the tissues of the missing
enzyme produced by healthy donor hematopoietic cells.
Case report
We present a case of 4-year-old girl with genetically
confirmed mevalonic kinase deficiency.
She has suffered from recurrent fever, lymphadenopa-
thy, hepatosplenomegaly, hepatitis, impaired growth
since she was born. Constant mevalonic acyduria was
the first key for diagnosis, then confirmed by genetical
analysis of MVK and lack of MK enzyme activity in
blood cells. The response to treatment with steroids and
IL1-blocker was poor, with only partial resolution of
autoinflammation and steroid-dependent adverse events.
Due to worsening clinical condition, at the age of 2.5
years patient received bone marrow transplantation
(BMT) from matched sibling donor. Due to decreasing
donor chimerism, the girl required second transplanta-
tion from the same donor at the age of 3 years, followed
by repeated donor lymphocyte infusions (DLI). Five
months after last DLI the patient achieved stable full
donor chimerism. At last follow up, 12 months after
HSCT, the girl is in excellent clinical condition, without
signs of autoinflammation for 7 last months, progress in
psychomotorical and physical development and good
immunological reconstitution was observed. Activity of
mevalonate kinase is present after transplantation,
although still below normal range and mevalonic acy-
duria is still observed. To assess further improvement of
laboratory markers and its clinical consequences longer
follow up of the patient is required.
Discussion
Presented case encourages to qualify patients with
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